After more than a decade with type 2 diabetes, you know how a visit goes. A number comes back from the lab and a prescription is renewed. You are reminded to watch what you eat. You pay around $600 a month for insurance. The control you were told to expect still has not come. In all those years, no clinician has sat down with you and explained the whole metabolic picture.
So when you look for type 2 diabetes telehealth and find a $299 monthly membership listed near Hims, Ro and MEDVi, your suspicion is reasonable. It can look like the same idea at a higher price. GoodLife Health manages type 2 diabetes online with a Hemoglobin A1c (HbA1c) every quarter and branded medication, including Mounjaro, where a clinician finds it indicated. It prescribes to the pharmacy you choose at that pharmacy's price and takes nothing on the medication.
You have heard claims before, so this piece shows its work. It explains where the money goes in each kind of service, what that means for someone with a long-standing metabolic condition and what the membership will not do for you. We do not know your numbers yet. No one should pretend to know them before the labs are drawn.
- At their published August 2026 prices, Hims and Ro bundle the medication into what they charge.
- GoodLife Health charges $299 a month for the care, the same whatever medication is indicated and whatever the dose.
- Medication goes to the pharmacy you choose at that pharmacy's price, with nothing taken on it.
- Every 90 days, the panel reads Hemoglobin A1c (HbA1c) beside Fasting Insulin, Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP and TSH With Reflex To Free T4.
- The membership pairs with your insurance and does not replace it.
- $598 is held for the first two months, released if a clinician cannot accept you and charged, non-refundable, once you are accepted.
A decade of treatment aimed at one number
Over the past decade, your care has most likely circled a single result. The A1C comes back. If it is high, a dose goes up or a second medication is added. If it is a little better, you hear that you are doing fine and the visit ends. The next appointment is months away. Between appointments, the plan's phone line and its portal are most of what you have.
None of this requires bad faith from anyone. A visit of a few minutes leaves room for one number and one decision, so the number that gets read is the one the diagnosis is built on. Glucose defines the condition on paper. It is still only one marker in a metabolism that produces many. In your case, the others seem to have gone unread.
Ask yourself a few plain questions. Has anyone measured your fasting insulin? Has anyone drawn ApoB or Lp(a), the cardiovascular markers that sit beyond a standard cholesterol result? Has your thyroid been checked lately? Did anyone connect that result to your weight or your energy? Have you ever seen your results laid side by side over time, with someone who explained what moved and why?
If the answer to most of these is no, the gap has little to do with your effort. You have probably been told at some point that the answer is discipline. That advice assumes the problem is already understood. What has been missing is a reading of the whole picture and a clinician who stays long enough to follow it from one season to the next.
Meanwhile, the premium keeps leaving your account every month. Around $600 a month does real work, because it is what stands between you and a hospital bill. It has not bought you a clinician who explains your metabolism. That is why the advertisements for online prescriptions start to look sensible. A questionnaire, a short review and a medication at your door would at least feel like movement. Then a membership appears that costs more than those apps. The obvious question follows. Is this the same thing at a higher price?
Where the money comes from decides what the care looks for
Our white paper on how GLP-1 telehealth companies make money sets out the three ways these businesses are paid. Some earn a margin on the medicine. Some charge a low membership fee and bill your insurance. Some charge one flat fee and send the medicine to a pharmacy at that pharmacy's own price. The way a company gets paid is the pressure its clinicians work under. It does not make anyone good or bad. It decides what the company is rewarded for.
Now read what the best-known apps publish. On their own pricing pages in August 2026, Hims listed branded Wegovy with clinical support at $299 a month and Zepbound at $399, priced as a bundle. Ro's advertised track at $149 to $249 a month was compounded semaglutide. MEDVi's pricing is not in our published comparison, so we will not describe its model. You can read its pricing page with the same questions in hand.
A weight program is built to give many people access to one class of drug at a price that is easy to say. That is a legitimate service. For some people it is enough.
Your situation asks a different question. You have a metabolic condition that has been treated for more than 10 years and is still not well controlled. After 10 years of treatment, the useful question is why the control never came. A program built around dispensing one drug has little reason to ask it.
After 10 years of treatment, the useful question is why the control never came.
The money explains the rest. When the medicine is inside the price, the company is paid when the prescription is filled. When the medicine sits outside the price, as it does here, the fee is the same whatever is prescribed and whatever the dose. Your clinician gains nothing from choosing one drug over another or from raising a dose. That is the case for the third model. It is also why the membership costs more than an app's headline fee. The company is paid for the care and for nothing else.
A second difference matters more for someone in your position. Diabetes care has long been run on glucose. Medicine is moving toward testing before treating, with fasting insulin and ApoB read where glucose and LDL used to stand alone. That is why fasting insulin and A1C are read together. ApoB can stay high after the weight comes down. A thyroid that is running slow can stall progress that every other number suggests should be happening. An A1C shows none of this.
Read together every quarter, these markers can help explain why years of treatment have not produced the control you expected. That work is what a membership like ours is for. Whether it is worth $299 a month depends on whether you want that work done.
What $299 a month does for long-standing type 2 diabetes
GoodLife Health is precision direct primary care for cardiometabolic optimization. In plain terms, that means diagnosis first, then treatment, then the long haul. GoodLife Health manages type 2 diabetes online with a Hemoglobin A1c (HbA1c) every quarter and branded medication, including Mounjaro, where it is indicated.
The path starts with an eligibility check, then an intake and a checkout. A clinician then reviews your case. Labs come before any prescription and every quarter after. Four cardiometabolic lab panels a year are included in the fee, one every 90 days. Each panel reads nine biomarkers, among them Hemoglobin A1c (HbA1c), Fasting Insulin, Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP and TSH With Reflex To Free T4. Every result is in your hands. You see the numbers your clinician sees. You see them move from one quarter to the next.
The clinicians are licensed in all fifty states. Yours stays with you from one quarter to the next. Between video visits, you can message the care team with the questions that come up.
For someone who has carried a diagnosis for more than 10 years, that continuity matters most. The first panel sets a baseline drawn with the whole picture in view, perhaps for the first time. The second shows what changed and what did not. By the fourth, you and your clinician are reading a year of your own metabolism. A single result read in a short visit cannot show you that.
With the first panel in hand, your clinician reads your A1C beside your fasting insulin, the lipid markers and the thyroid result. You talk through what they mean together on a video visit before anything changes. If a medication change makes sense, your clinician makes it with you. The next panel shows what it did.
When a medication is clinically indicated, it is branded and FDA-approved. For type 2 diabetes, that can mean Mounjaro or Ozempic. Wegovy and Zepbound are prescribed where they are the indicated choice. Any FDA-approved medication your clinician judges indicated can be prescribed. It goes to the pharmacy you choose at that pharmacy's price. GoodLife Health sets nothing, sees nothing and takes nothing on it.
Ozempic and Mounjaro are the diabetes brands of semaglutide and tirzepatide. Whether either belongs in your treatment is decided by your clinician with you, after the labs.
You keep your insurance. Whether your plan covers a medication is between you, your plan and your pharmacy. We do not promise coverage. Prior authorization is the pharmacy's process. We do not run it, speed it or win it.
If you pay for medication yourself, the manufacturers now publish their own prices. As of September 2026, NovoCare listed Wegovy pens at $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after. The Wegovy pill started from $149 a month at lower doses. LillyDirect listed Zepbound vials at $299 to $449 a month depending on dose. Those prices belong to the manufacturers. Your membership fee does not move with them. It is the same whatever medication is indicated and whatever the dose.
There is one more answer to the Ro comparison. GoodLife Health prescribes no compounded GLP-1. The FDA does not approve compounded GLP-1 drugs. It has also published its concerns about unapproved GLP-1 drugs used for weight loss. Our choice means members pay the branded price, which is higher. We made it anyway, because a clinician's license carries the responsibility for what is prescribed.
You should know the membership's limits before you pay. It does not replace your insurance. Keep the plan for the hospital and for catastrophic cover. Its scope is cardiometabolic care, which is narrower than full-scope primary care. It makes no promise about weight, A1C, remission or a cure. We don't promise the membership fee is HSA or FSA eligible. Your account administrator decides, so check with them before using those funds.


Who this is not for
Some people should not pay for this membership. If you want a prescription and nothing more, a manufacturer's direct channel or a bundled app may suit you better. Paying for care you will not use helps nobody.
If you want compounded GLP-1, we do not prescribe it. If your diabetes is well controlled and you already have a clinician who reads your whole picture with you, keep that clinician. If you hope a membership will replace your insurance, this one will not. If you need in-office procedures or care well outside cardiometabolic health, the membership does not provide them.
Not everyone who applies is accepted. A clinician reviews every case after the checkout. If the clinician cannot accept you into care, the $598 hold is released and you are never charged. If you are accepted, the first two months are charged and are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy.
A plain answer and one thing to do this week
So is GoodLife Health a Hims, Ro or MEDVi at a higher price? No. At their published prices, Hims and Ro put the medication inside what they sell. The membership charges for the clinical work around your metabolism and leaves the medication at the pharmacy's price.
Whether or not you join, do one thing this week. Ask your current practice for your A1C results from the last several years and put them in order. Ask whether fasting insulin, ApoB, Lp(a), hs-CRP or a thyroid test has ever been drawn. Write down every medication you take and its dose. That page is the start of the whole picture. Bring it to whichever clinician you choose. If you are comparing services, ask each one three questions. Is the medicine inside the price? Are labs drawn before the prescription and after it? Will the same clinician read them with you next quarter? Our comparison of the true monthly cost of GLP-1 telehealth lays the published prices side by side.
The membership is $299 a month. At sign-up, $598 is held on your card for the first two months. It is charged only once a clinician accepts you. From then, those two months are non-refundable. If you are not accepted, the hold is released and you are never charged. From month three, the membership is month to month. The fee buys a lab panel every 90 days, a clinician who stays, messaging with the care team and video visits. Medication, when it is indicated, goes to your pharmacy at that pharmacy's price with nothing taken on it. What the membership returns is the explanation 10 years of visits never produced, your markers followed quarter by quarter and the end of the eight-minute visit. It is different because it tests first, treats second and sells neither the drug nor the dose. If you pay around $600 a month for insurance and still have no one who has explained your metabolism, each quarter you wait is a quarter without a baseline.
Related Reading
- How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
- The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss